112 related articles for article (PubMed ID: 7991520)
1. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.
Costa MJ; Vogelsan J; Young LJ
Mod Pathol; 1994 Aug; 7(6):619-27. PubMed ID: 7991520
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases.
Costa MJ; Walls J
Cancer; 1996 Feb; 77(3):533-42. PubMed ID: 8630962
[TBL] [Abstract][Full Text] [Related]
3. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
4. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
5. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
8. [p53 in urogenital tumors:analysis of expression and mutation].
Löning T; Schlechte H; Friedrichs K; Schnoor D; Ditscherlein G; Bommer G; Löning S
Verh Dtsch Ges Pathol; 1993; 77():117-8. PubMed ID: 7511267
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.
Baas IO; Mulder JW; Offerhaus GJ; Vogelstein B; Hamilton SR
J Pathol; 1994 Jan; 172(1):5-12. PubMed ID: 7931827
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of p53-related proteins predicts rapid growth rate of head and neck cancer.
Edström S; Cvetkovska E; Westin T; Young C
Laryngoscope; 2001 Jan; 111(1):124-30. PubMed ID: 11192880
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
14. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutations in human epithelial skin cancers.
Molès JP; Moyret C; Guillot B; Jeanteur P; Guilhou JJ; Theillet C; Basset-Sèguin N
Oncogene; 1993 Mar; 8(3):583-8. PubMed ID: 8437842
[TBL] [Abstract][Full Text] [Related]
16. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.
Visscher DW; Sarkar FH; Shimoyama RK; Crissman JD
Diagn Mol Pathol; 1996 Sep; 5(3):187-93. PubMed ID: 8866232
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases.
Nagao T; Gaffey TA; Serizawa H; Sugano I; Ishida Y; Yamazaki K; Tokashiki R; Yoshida T; Minato H; Kay PA; Lewis JE
Mod Pathol; 2003 Dec; 16(12):1265-72. PubMed ID: 14681328
[TBL] [Abstract][Full Text] [Related]
19. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
Amatya VJ; Takeshima Y; Kaneko M; Inai K
Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.
Essner R; Kuo CT; Wang H; Wen DR; Turner RR; Nguyen T; Hoon DS
Cancer; 1998 Jan; 82(2):309-16. PubMed ID: 9445187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
